Although GLP-1 agonists have many positive benefits, they do have a number of potential side effects
Mycol 52, 422426
At the initial baseline visit, serial venous sampling performed after oral d 3 -l-carnitine challenge revealed rapid increases in plasma concentrations of d 3 -l-carnitine, and subsequent increases in d 3 -BB and d 3 -TMAO following a lag phase (Figure 1, AC, filled circles)
One year post-discontinuation, 35.2% of patients (2,794) received an alternative obesity treatment: 27.4% received another medication, 13.7% received modifications and visits with a health care professional, and 0.6% received metabolic or bariatric surgery
They may suggest lifestyle changes, medication adjustments, or other treatments before recommending stopping semaglutide